MPNRF | April 29, 2021
January 29, 2015
The New England Journal of Medicine has just published a paper co-authored by Claire N. Harrison, D.M., Ruben Mesa, M.D. and Srdan Verstovsek, M.D., Ph.D. among others, describing the outcome of a trial measuring Ruxolitinb in polycythemia vera patients who are intolerant or who do not respond to Hydroxyurea. Patients were randomly assigned either Ruxolitinib or phlebotomy treatment for this trial. The results suggested that patients had better hematocrit control and reduced spleen size on Ruxolitinib versus phlebotomy. Read the full article: http://www.nejm.org/doi/full/10.1056/NEJMoa1409002
